Standard Biotools is trading at $0.64, down 5.26%, as the cause of its October 8, 2026 decline remains uncertain.
- No clear company-specific announcement explaining the decline surfaced in available coverage. The latest identified company announcement was the October 5 agreement to sell its Microfluidics business to ARCHIMED; this is not established as the cause.
- Broader markets were softer, but listed index declines were modest, and healthcare was higher, so neither clearly explains the drop.